Brief: Innovent Biologics Says Q3 2026 Product Revenue Exceeds RMB4.7 Bln
29/10/2026 01:11
BRIEF-Innovent Biologics Says Q3 2026 Product Revenue Exceeds RMB4.7 Bln Oct 29 (Reuters) - Innovent Biologics, Inc. 1801.HK:
Q3 2026 PRODUCT REVENUE EXCEEDS RMB4.7 BILLION, UP OVER 40% YEAR-OVER-YEAR
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsPfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis
Brief: Innovent Biologics Says Q3 2026 Product Revenue Exceeds RMB4.7 Bln
Takeda to seek Japan approval for gastric cancer drug next year
Advisory: Alert on Innovent Biologics Phase 3 study results withdrawn